Linkedin
RLS logo_header
Linkedin

Guardant Health and Pfizer to Develop and Commercialize New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform

“Guardant Health, Inc., a leading precision oncology company, today announced a strategic collaboration with Pfizer, Inc., to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity™ smart liquid biopsy platform. Under the multi-year collaboration agreement, Guardant and Pfizer aim to utilize Guardant’s portfolio of liquid biopsy tests in Pfizer’s global clinical studies, and evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) level as a surrogate endpoint to monitor therapy response and (b) related blood-based epigenomic analyses.”

Read the full story on "Guardant Health and Pfizer to Develop and Commercialize New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform"

Share:

More News

Positive Immune Response Data Announced from FLAMINGO-01 Ph 3 Trial

CEO Snehal Patel commented, “We are very encouraged to see that the preliminary results from FLAMINGO-01 show immune responses in both HLA-A*02 and non-HLA-A*02 patients. We are now considering the merits of adding a randomized placebo arm for non-HLA-A*02 patients, transforming this current open label third arm into effectively a

Initial Data from Ph 3 Trial Demonstrating 75% CRR at 3 Months with nadofaragene firadenove) in BCG-unresponsive Japanese NMIBC Patients Announced 

“At Ferring, we are committed to meeting the unmet needs in bladder cancer care and equipping uro-oncologists with critical evidence they need to deliver effective, and life-changing treatment,” said Joern Jakobsen, M.D., Ph.D., Vice President and Head of Global Research and Medical for Uro-Oncology and Urology, Ferring Pharmaceuticals. “These new

Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals

“We recognise the significance of Mosaic’s platform, which has identified these two assets as anchor components of a pipeline of potential combination products,” said Dr. Harren Jhoti, co-founder, president and chief executive officer of Astex. “Both drug targets are well-characterised drivers of many cancers, and we are excited to be

Second Interim Analysis of OBI-822 Ph 3 Trial Completed and Trial Termination announced

“We do not view today’s unsatisfactory outcome as a failure of Globo H,” Dr. Heidi Wang, CEO of OBI Pharma added. “There may come a time, with a deeper scientific understanding of the Globo H function, it may play a meaningful role once again.”

Onco-This-Week

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.